and cabozantinib for advanced RCC
388 doi: (Published 26 February 2025) Cite this as: BMJ 2025;388:e080679 Linked Editorial GLP-1 receptor agonists and suicidality Samantha B Shapiro, doctoral student1 2, Hui Yin, statistician1, Oriana Hoi Yun Yu, endocrinologist and associate professor2 3 4, Soham Rej, psychiatrist and associate professor5 6, Samy Suissa, professor1 2 7, Laurent Azoulay, professor1 2 8 1 Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada 2 Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada 3 Division of Endocrinology, Jewish General Hospital, Montreal, QC, Canada 4 Division of Endocrinology & Metabolism, McGill University, Montreal, QC, Canada 5 Department of Psychiatry, Jewish General Hospital, Montreal, QC, Canada 6 Department of Psychiatry, McGill University, Montreal, QC, Canada 7 Department of Medicine, McGill University, Montreal, QC, Canada 8 Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada Correspondence: L Azoulay laurent mcgill.ca (or @profLAzoulay on X) Accepted 24 January 2025 Abstract Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors
This guide from the Centre for Addiction and Mental Health outlines how to talk about suicide with someone you're worried about
This diagram from Qin et al
Allergic Reactions Description : Rash, itching, swelling, severe dizziness, and trouble breathing
